Indeed, pathogenic IFNγ+ IL-17A+ cells have been identified in numerous disease settings, including multiple sclerosis (MS) and inflammatory bowel disease (IBD)7, 8, and exacerbate inflammatory disease in mouse models of these autoimmune conditions9–11. Here, IL17A is linked to inflammatory bowel disease.